

To,
BSE Limited,
Floor 25, P J Towers,
Dalal Street, Mumbai – 400001
Script Code: 543939

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held today on 10th November, 2023

Dear Sir/Madam,

This is to inform you that, the Board of Directors at their meeting held on today i.e. 10th November, 2023 at 02:30 P.M. at Shelter Nagar, Nr. S. T. Bus Stand, Himmatnagar GJ 383001 IN, interalia considered and approved the following matter:

1. Approval of Standalone Unaudited Financial Result for the Half Year ended on 30th September, 2023 as per Regulation 33 of the SEBI (LODR) Regulations, 2015 along with Limited Review report;
2. Appointment of M/s. Murtuza Mandorwala & Associates, Practicing Company Secretary, as Secretarial Auditor of the Company for the Year 2023-24;
3. Appointment of CA Mohammadaltaf Rasulbhai Sachora (ALTAF SACHORA & CO), FRN NO: 138017W, Ahmedabad , as Internal Auditors of the Company to conduct the Internal Audit for the financial year 2023-24.

The Board Meeting started at 02:30 P.M. and ended on 03:15 P.M.

Kindly acknowledge the receipt and update your website with the same.

Thanking You.

For, Shelter Pharma Limited

Mr. Mustaqim Nisarahmed Sabugar
DIN: 01456841
Managing Director
Date: 10th November, 2023
Place: Himmatnagar

CC: Attachments as mentioned in point 1 to 3 above



Mendajiwala & Co.

Chartered Accountant

Ref. No. :

Date :

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of the SHELTER PHARMA LIMITED for the half year ended on September 30, 2023 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


To,
The Board of Directors of
Shelter Pharma Limited

We have reviewed the accompanying statement of standalone unaudited financial results of **SHELTER PHARMA LIMITED (the "Company") (PAN: AALCS3158D)** for the period ended 30/09/2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 'Interim Financial Reporting' ('AS 25'), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the SEBI Listing Regulations'). Our responsibility is to issue a report on the Statement based on our review. Our responsibility is to express a conclusion on the statement based on our review.

Scope of our review

We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by ICAI. A review of statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





Mendajiwala & Co.

Chartered Accountant

Ref. No. :

Date :

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of these matters.


For, Mendajiwala & Co.
Chartered Accountants
(Firm Reg. No.: 0135065W)

Date: November 10, 2023
Place: Ahmedabad

MOHAMMEDSOEL N Mendajiwala
Proprietor

Membership No.: 146324

UDIN: 23146324BGV PRT 1023




SHELTER PHARMA LIMITED
CIN NO.U24233GJ2007PLC051956



Statement of Standalone Unaudited Financial Result for the period ended September,30 2023

(Rs.In Lakhs)

Sr. No	Particulars	For the Six Month Ended			For the year ended
		30.09.2023	31.03.2023	30.09.2022	31.03.2023
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
	Income				
I	Revenue from operations	1,931.20	1,913.48	1,701.79	3,615.27
II	Other Income	0.13	0.10	0.13	0.24
III	Total Income (I +II)	1,931.34	1,913.58	1,701.93	3,615.51
IV	Expenses				
	(a) Cost of Material Consumed	1,425.81	1,391.03	1,240.19	2,631.22
	(b) Purchases of Stock-in-Trade				
	(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-10.50	-6.54	0.57	-5.97
	(d) Employee Benefit Expense	38.47	30.95	24.51	55.45
	(e) Finance Cost	4.66	0.59	0.79	1.39
	(f) Depreciation & Amortised Expense	11.98	8.21	8.21	16.41
	(g) Other Expenses	48.92	61.07	60.80	121.87
	Total Expenses	1,519.34	1,485.30	1,335.07	2,820.38
V	Profit before exceptional and extraordinary items and tax (III - IV)	411.99	428.28	366.85	795.14
VI	Exceptional Items				
	Prior Period Items		45.00	45.00	90.00
VII	Profit before extraordinary items and tax (V - VI)	411.99	383.28	321.85	705.14
VIII	CSR Provision		6.96		6.96
IX	Profit before tax (VII - VIII)	411.99	376.32	321.85	698.18
X	Tax expense:				
	(1) Current tax	103.70	94.72	81.01	175.73
	(2) Deferred tax	-1.85	0.93	0.93	1.87
	(3) Prior Period tax				
	(4) Less : TDS				
XI	Profit/(Loss) for the period from continuing operations (IX - X)	310.14	280.67	239.91	520.58
XII	Profit/(loss) from discontinuing operations				
XIII	Tax expense of discounting operations				
XIV	Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)				
XIII	Profit/(Loss) for the period (XI + XIV)	310.14	280.67	239.91	520.58
XVI	Earning per equity share of Rs.10 each				
	(1) Basic	2.68	3.62	49.57	4.50
	(2) Diluted	2.68	3.62	49.57	4.50



Date : 10.11.2023
Place : Himmatnagar

For, Shelter Pharma Limited

Mr. Mustaqim Nisar Ahmed Sabugata
Chairman & Managing Director
DIN : 01456841




SHELTER PHARMA LIMITED

CIN NO.U24233GJ2007PLC051956


Statement of Standalone Assets and Liabilities as on September 30,2023
(Rs.In Lakhs)

Particulars	For the period ended on 30.09.2023	For the year ended on 31.03.2023
	(Un-Audited)	(Audited)
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	1,155.98	774.38
(b) Reserves and Surplus	2,113.99	680.50
(2) Non-Current Liabilities		
(a) Long-Term Borrowings		48.00
(b) Deferred Tax Liabilities (Net)		12.29
(c) Other Long Term liabilities		
(d) Long term Provisions	4.90	4.90
(3) Current Liabilities		
(a) Short-Term Borrowings	45.44	130.41
(b) 1. Trade Payables - others	21.14	45.63
2. Trade Payables - MSME	2.33	1.12
(c) Other Current Liabilities	24.09	262.37
(d) Short-Term Provisions	88.95	185.25
Total Equity & Liabilities	3,456.81	2,144.84
II. ASSETS		
(1) Non-Current Assets		
(a) Plant, Porperty & Equipments and Intangible Assets		
(i) Plant, Porperty & Equipments	179.49	184.51
(ii) Intangible Assets	0.15	
(b) Non-current Investments	67.63	67.63
(c) Deferred tax assets (net)	3.72	-
(d) Long term loans and advances	18.46	21.12
(e) Other Non-Current Assets		
(2) Current Assets		
(a) Current investments		
(b) Inventories	920.31	796.45
(c) Trade receivables	948.83	819.47
(d) Cash and cash Equivalent	412.66	42.85
(e) Short-term loans and advances	689.38	0.10
(f) Other Current Assets	216.19	212.72
Total Assets	3,456.81	2,144.84



For, Shelter Pharma Limited


Mr. Mustaqim Nisar Ahmed
Chairman & Managing Director

DIN : 01456841

Date : 10.11.2023

Place : Himmatnagar

SHELTER PHARMA LIMITED

CIN NO. U24233GJ2007PLC051956




Statement of Cash Flow for the half year ended on September 30, 2023

(Rs. In Lakhs)

Particulars		For the Period ended	For the year ended on
		on 30.09.2023	31.03.2023
		(Un-Audited)	(Audited)
A) CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit / (Loss) Before Tax & Extra Ordinary Items:		411.99	705.14
Adjustments For:			
Depreciation & Amortization Expense		11.98	16.41
Provision for Gratuity		-	1.16
Bad debt		-	-
Deferred tax exp / income		-	-
Non-operating income (Intrest Received, etc)		(0.13)	(0.24)
Operating Profit Before Working Capital Changes	i.	423.84	722.47
Adjustments For:			
(Increase)/ Decrease in Inventories		(123.85)	-229.03
(Increase)/ Decrease in Trade Receivables		(129.36)	-658.92
(Increase)/ Decrease in Short Term Loans & Advances		(689.28)	-0.10
(Increase)/ Decrease in Other Current Assets		(3.48)	32.40
Increase/ (Decrease) in Trade Payable		(23.28)	14.50
Increase/ (Decrease) Other Current Liabilities		(238.28)	-4.09
Increase/ (Decrease) Short Term Borrowings		(84.97)	117.29
Increase/ (Decrease) Short term provision		(200.00)	-90.91
Cash Generated From Operations	ii.	(1,492.50)	-818.86
Income Tax Paid	i+ii		
Net Cash From Operating Activities	(A)	(1,068.66)	-96.38
B) CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Fixed Assets		-7.12	-0.41
Purchase of Shares & Funds		-	0.00
Repayment of Long Term Loans & Advances		2.65	11.52
Intrest Received		0.13	0.24
Net Cash From Investing Activities	(B)	(4.33)	11.34
C) CASH FLOW FINANCING ACTIVITIES			
Proceeds from issuance of Share Capital		1490.80	-20.11
Increase / (Decrease) in Long term Borrowings		-48.00	48.00
Net Cash From Financing Activities	(C)	1,442.80	27.89
Increase in Cash and Cash Equivalents	(D)	369.81	(57.15)
(A)+(B)+(C)			
Cash and Cash Equivalents at the Beginning of the Year	(E)	42.85	10.01
Cash and Cash Equivalents at the End of the Year	(D) +(E)	412.66	42.85
Components of Cash and Cash Equivalents:			
Cash on Hand		61.44	34.61
Other Bank Balances		351.22	8.24
Total		412.66	42.85

Notes:

- 1) The cash flow statement has been prepared in accordance with the requirement of Companies Act 2013.
- 2) Figures in brackets indicate Cash Outflow
- 3) The previous year's figures have been regrouped/restated wherever necessary to conform to this period's



For, Shelter Pharma Limited



Mr. Mustaqim Nisar Ahmed Sabugar
Chairman & Managing Director
DIN : 01456841

Place : Himmatnagar
Date : 10.11.2023

Notes:

1. The above statement of unaudited standalone financial results of Shelter Pharma Limited ("the company"), which have been prepared in accordance with the Accounting standard prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued hereunder, other accounting principles generally accepted in India and guide line issued by the securities and Exchange Board of India ("SEBI") were reviewed and recommended by the audit committee and approved by the board of directors at their meeting held on 10th November, 2023 .
2. The statutory Auditors have carried out a limited review on the unaudited standalone financial results and issued unmodified report thereon.
3. The figure for the previous year / period have been regrouped wherever necessary, to make the comparable.

For, Shelter Pharma Limited



Mr. Mustaqim Nisar Ahmed Sabugar
Chairman & Managing Director
DIN : 01456841



“Annexure-I”

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015.

Sr. No.	Details of events that needs to be provided	Information of such event(s)
1.	Reason for Change viz. Appointment	Appointment: In Order to comply with the provision of section 204 of the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2.	Date of Appointment	Date: 10th November, 2023
3.	Brief Profile	Attached as Annexure II
4.	Term of Appointment	For F.Y. 2023-24

Annexure II

NAME	M/S Murtuza Mandorwala & Associates
Date Appointment	10 th November, 2023
Term of Appointment	F.Y. 2023-24 (1 year from the date of appointment)
Address	B-503, Sivanta One, Pritamnagar Cross road, Near V.S. Hospital, Ellisbridge, Ahmedabad-380006
Contact	09409020523
Qualification	<ul style="list-style-type: none"> ✓ Member of Institute of Company Secretaries of India ✓ Bachelor in Commerce from Gujarat University ✓ Masters in Commerce from Indira Gandhi National University ✓ Bachelor of Law from Gujarat University ✓ DLP: Diploma in Labour Practice from Gujarat
Area of Practice	Corporate & LLP Laws, SME Advisory, Compliance, Due Diligence, FDI & FEMA advisory, NBFC Laws, Capital Markets & Securities Laws Advisory, Taxation, Audit & Certifications, Legal Compliances, Corporate Governance, Corporate Social Responsibility and allied services.

Shelter Pharma Limited

Regd. Office & Works: Shelternagar, Opp. Bus Station, Himatnagar-383001 Gujarat, India. Phone: +91 2772 240108/246995

Email: info@shelter.co.in

CIN: U24233GJ2007PLC051956

Service Provided	Corporate & LLP Laws, SME Advisory, Compliance, Due Diligence, FDI & FEMA advisory, NBFC Laws, Capital Markets & Securities Laws Advisory, Taxation, Audit & Certifications, Legal Compliances, Corporate Governance, Corporate Social Responsibility and allied services.
Peer-review no.	1615/2021
M. No.	F10745
C.P.No.	14284

For, Shelter Pharma Limited

Mr. Mustaqim Nisarahmed Sabugar
DIN: 01456841
Managing Director

Date: 10th November, 2023
Place: Himmatnagar

“Annexure-I”

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015.

Sr. No.	Details of events that needs to be provided	Information of such event(s)
1.	Reason for Change viz. Appointment	Appointment: In Order to comply with the provision of section 138 of the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2.	Date of Appointment	Date: 10th November, 2023
3.	Brief Profile	CA Mohammadaltaf Rasulbhai Sachora (ALTAFSACHORA &CO.), Chartered Accountants Firm Working For more than 10 Years in the field of Company Audit, Tax Audit, Accounting, GST Audit, Company Law Matters, Income Tax Matters, Sales Tax Matters, Sales Tax Matters, Transactional Audit etc. and valuation work from last 2 years.
4.	Term of Appointment	For F.Y. 2023-24

For, Shelter Pharma Limited

Mr. Mustaqim Nisarahmed Sabugar
DIN: 01456841
Managing Director

Date: 10th November, 2023
Place: Himmatnagar